Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2014

01-03-2014 | Original Article

Chimerism status is correlated to acute graft-versus-host disease after allogeneic stem cell transplantation

Authors: Ying Jiang, Li-ping Wan, You-wen Qin, Xiao-rui Wang, Shi-ke Yan, Kuang-cheng Xie, Chun Wang

Published in: International Journal of Hematology | Issue 3/2014

Login to get access

Abstract

To evaluate the correlation between chimerism status and acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation. Chimerism of peripheral blood of 124 patients was monitored at regular intervals post-transplant. The chimerism of 124 post-transplant cases of CD3+T lymphocytes, 107 cases of CD3−CD56+CD16+NK lymphocytes, 49 cases of CD15+ granulocytes, and 27 cases of CD19+B lymphocytes sorted by fluorescence-activated cell sorter were analyzed by polymerase chain reaction amplification of short tandem repeats. Differences were found in the time between establishment of full donor T-cell chimerism and the occurrence of aGVHD (P = 0.035, two related samples test). Patients with ≥69 % donor chimerism on day +7 in T-cells had higher rates of aGVHD. This study may provide a rational basis for treatment with adoptive immunotherapy at an earlier time, such as day 7 after SCT, than at present to prevent aGVHD.
Literature
1.
Storb R. Allogeneic hematopoietic cell transplantation: a historical perspective. Transfus Med Hemother. 2004;31:21–32.CrossRef
2.
Maury S, Jouault H, Kuentz M, Vernant JP, Tulliez M, Cordonnier C, et al. Chimerism analysis by lineage-specific fluorescent polymerase chain reaction in secondary graft failure after allogeneic stem cell transplantation. Transplantation. 2001;71(3):374–80.PubMedCrossRef
3.
Jiang Y, Wan LP, Wang C, Yan SK, Gao YR, Jiang JL, et al. Clinical significance of dynamic monitoring of cell chimerism following allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2008;29(10):667–71.PubMed
4.
Mattsson J, Uzunel M, Remberger M, Ringdén O. Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation. Bone Marrow Transpl. 2003;32(5):477–83.CrossRef
5.
Balon J, Hałaburda K, Bieniaszewska M, Reichert M, Bieniaszewski L, Piekarska A, et al. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease. Bone Marrow Transpl. 2005;35(11):1083–8.CrossRef
6.
Tsutsumi Y, Tanaka J, Kato N, Zhang L, Mori A, Kobayasi R, et al. Analysis of mixed chimerism in patients after allogeneic stem cell transplantation using a capillary electrophoresis system. Acta Haematol. 2002;107(4):195–202.PubMedCrossRef
7.
Jaksch M, Uzunel M, Remberger M, Sundberg B, Mattsson J. Molecular monitoring of T-cell chimerism early after allogeneic stem cell transplantation may predict the occurrence of acute GVHD grades II–IV. Clin Transpl. 2005;19(3):346–9.CrossRef
8.
Valcárcel D, Martino R, Caballero D, Mateos MV, Pérez-Simón JA, Canals C, et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transpl. 2003;31(5):387–92.CrossRef
9.
Nollet F, Billiet J, Selleslag D, Criel A. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing. Bone Marrow Transpl. 2001;28:511–8.CrossRef
10.
Kristt D, Stein J, Yaniv I, Klein T. Assessing quantitative chimerism longitudinally: technical considerations, clinical applications and routine feasibility. Bone Marrow Transpl. 2007;39:255–68.CrossRef
11.
Mattsson J, Uzunel M, Remberger M, Ringden O. T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation. 2001;71:433.PubMedCrossRef
12.
Li SX, Zhu HL, Guo B, Da WM. Application of short-tandem-repeat amplification and fluorescent-multiplex PCR for chimerism analysis. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011;19(3):749–53.PubMed
13.
Svenberg P, Mattsson J, Ringdén O, Uzune M. Allogeneic hematopoietic SCT in patients with non-malignant diseases, and importance of chimerism. Bone Marrow Transpl. 2009;44(11):757–63.CrossRef
14.
Johannes S, Alexander K, Mare S, Gerhard E, Martin B. T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation. Cancer Immunol Immunother. 2005;54:1043–58.CrossRef
15.
Perez-Simon JA, Caballero D, Diez-Campelo M, Lopen-Perez R, Mateos G, Canizo C, et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia. 2002;16:1423–31.PubMedCrossRef
16.
Rupa-Matysek J, Lewandowski K, Nowak W, Sawiński K, Gil L, Komarnicki M. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Proc. 2011;43(5):1915–23.CrossRef
17.
Childs R, Clave E, Contenin N, Jayasekera D, Hensel N, Leitman S, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full fonor T-cell chimerism precedes alloimmune responses. Blood. 1999;94:3234–41.PubMed
18.
Lim ZY, Pearce L, Ingram W, Ho AYL, Mufti GJ, Pagliuca A. Chimerism does not predict for outcome after alemtuzumab-based conditioning: lineage-specific analysis of chimerism of specific diseases may be more informative. Bone Marrow Transpl. 2008;41(6):587–8.CrossRef
19.
Besien K, Dew A, Lin S, et al. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymph. 2009;50(11):1809–17.CrossRef
20.
Mossallam GI, Kamel AM, Storer B, Martin PJ. Prognostic utility of routine chimerism testing at 2 to 6 months after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2009;15(3):352–9.CrossRef
21.
Montero A, Savani BN, Kurlander R, Read EJ, Leitman SF, Childs R, et al. Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning. Br J Haematol. 2005;130:733–9.PubMedCrossRef
22.
Mohty M, Avinens O, Faucher C, Viens P, Blaise D, Elia JF. Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica. 2007;92(7):1004–6.PubMedCrossRef
23.
Baron F, Baker JE, Storb R, Gooley TA, Sandmaier BM, Maris MB, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2004;104(8):2254–62.PubMedCrossRef
24.
Alcoceba M, Balanzategui A, Díez-Campelo M, Martín-Jiménez P, Sarasquete ME, Chillón MC, et al. Clinical and prognostic value of discrepancies in microsatellite DNA regions between recipient and donor in human leukocyte antigen-identical allogeneic transplantation setting. Transplantation. 2008;86(7):983–90.PubMedCrossRef
25.
Miura Y, Tanaka J, Toubai T, Tsutsumi Y, Kato N, Hirate D, et al. Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and non-myeloablative stem cell transplantation. Bone Marrow Transpl. 2006;37(9):837–43.CrossRef
26.
Bacigalupo A, Lamparelli T, Milone G, et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day +7 after alternative donor transplants. Bone Marrow Transpl. 2010;45:385–91.CrossRef
Metadata
Title
Chimerism status is correlated to acute graft-versus-host disease after allogeneic stem cell transplantation
Authors
Ying Jiang
Li-ping Wan
You-wen Qin
Xiao-rui Wang
Shi-ke Yan
Kuang-cheng Xie
Chun Wang
Publication date
01-03-2014
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2014
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-014-1510-5

Other articles of this Issue 3/2014

International Journal of Hematology 3/2014 Go to the issue

Erratum

Erratum to: A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia

Original Article

The impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy

Progress in Hematology

Microenvironment of adult T-cell leukemia/lymphoma-associated nodal lesions

Original Article

Descriptive profile of β-thalassemia mutations in West Bengal population: a hospital-based study

Progress in Hematology

Molecular genetics of peripheral T-cell lymphomas

Progress in Hematology

Peripheral T cell lymphoma in Asia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits